Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | CCR1 | P32246 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636927 | 0.90 | HPGDS (0.76) | HPGDSALDH1A1GAAHSD17B10CCR1 | |
| SCHEMBL4636873 | 0.89 | HPGDS (0.70) | HPGDSROCK2PRKACAGRK5PRKX | |
| SCHEMBL16495368 | 0.89 | HPGDS (0.59) | HPGDSALDH1A1GAAHSD17B10CCR1 | |
| SCHEMBL4636491 | 0.88 | HPGDS (0.74) | HPGDSALDH1A1CCR1ROCK2PRKACA | |
| SCHEMBL4636627 | 0.88 | HPGDS (0.74) | HPGDSALDH1A1GAAHSD17B10CCR1 | |
| SCHEMBL4636188 | 0.87 | HPGDS (0.65) | HPGDSROCK2PRKACAGRK5PRKX | |
| SCHEMBL4636739 | 0.85 | HPGDS (0.70) | HPGDSALDH1A1CCR1ROCK2PRKACA | |
| SCHEMBL4636413 | 0.85 | HPGDS (0.75) | HPGDSALDH1A1CCR1ROCK2PRKACA | |
| SCHEMBL4636381 | 0.85 | HPGDS (0.69) | HPGDSCCR1ROCK2PRKACAGRK5 | |
| SCHEMBL5015736 | 0.85 | HPGDS (1.00) | HPGDSALDH1A1CCR1PRKACAGRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | HPGDS 16/4885ALDH1A1 871/4885GAA 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.